Gabapentin
Product Images NDC 67046-229

9 FDA label images from Contract Pharmacy Services-pa · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 67046-229). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Gabapentin Tablets Usp 800 mg 100 Tablets (800mg Label)

Gabapentin Tablets Usp 800 mg 100 Tablets (800mg Label)
Gabapentin 800 mg tablet bottle label with a quantity of 30 tablets. The label includes storage instructions, barcode, lot number 02140575, pill ID G 13, and expiration date 06/03/15. Packaged by Contract Pharmacy Services-PA, manufacturer Glenmark, with NDC 67046-229-30.*
FDA Label Image

Figure 1 (Fig 1)

Figure 1 (Fig 1)
A line graph comparing mean pain scores over an 8-week period between a placebo group and a Gabapentin 3600 mg/day group. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores. The Gabapentin group demonstrates a decreasing pain score trend, while the placebo group remains relatively stable.*
FDA Label Image

Figure 2 (Fig 2)

Figure 2 (Fig 2)
Line chart showing mean pain scores over 7 weeks, comparing placebo and two Gabapentin dosages (1800 mg/day and 2400 mg/day). The x-axis represents weeks, while the y-axis shows mean pain scores. The chart includes a 3-week dose titration period followed by a 4-week fixed dose period.*
FDA Label Image

Figure 3 (Fig 3)

Figure 3 (Fig 3)
Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to Gabapentin (GBP) at doses of 3600 mg, 1800 mg, and 2400 mg in two studies. The chart shows higher responder percentages for Gabapentin versus placebo in both studies, with statistical significance noted.*
FDA Label Image

Figure 4 (Fig 4)

Figure 4 (Fig 4)
A chart showing the percentage difference versus daily dose (mg) for Gabapentin in three studies labeled STUDY a, STUDY b, and STUDY c. The x-axis represents daily doses from 600 mg to 1800 mg, and the y-axis represents difference percentages ranging from 2% to 22%. Data points for each study are marked with different fills and labeled accordingly.*
FDA Label Image

Equation 1 (Image 01)

Equation 1 (Image 01)
An illustrated formula showing the calculation for creatinine clearance (CLCr). It includes age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier for female patients (0.85). This formula is used in clinical settings to estimate kidney function.*
FDA Label Image

Glenmark Logo 2 (Logo 01)

Glenmark Logo 2 (Logo 01)
FDA Label Image
Glenmark Logo (Logo)
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure diagram of gabapentin showing its molecular arrangement, including amino and carboxyl groups attached to a cyclohexane ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.